Journalartikel
Autorenliste: Perletti, G.; Skerk, V.; Magri, V.; Markotic, A.; Mazzoli, S.; Parnham, M. J.; Wagenlehner, F. M. E.; Naber, K. G.
Jahr der Veröffentlichung: 2011
Seiten: 1035-1044
Zeitschrift: Molecular Medicine Reports
Bandnummer: 4
Heftnummer: 6
ISSN: 1791-2997
eISSN: 1791-3004
Open Access Status: Bronze
DOI Link: https://doi.org/10.3892/mmr.2011.575
Verlag: Spandidos Publications
Abstract:
Chronic bacterial prostatitis (CBP) is a persistent infection of the prostate characterized by poor quality of life mainly due to frequent relapse episodes caused by incomplete eradication of causative pathogens. Aggressive antibacterial therapy is required to attenuate the severe symptoms of CBP and to achieve a permanent cure. Although fluoroquinolones are currently recommended as first-choice agents, macrolide antibiotics are emerging as a noteworthy option for the treatment of CBP. Macrolide antibiotics are characterized by an impressive array of distinct pharmacokinetic (PK) and pharmacodynamic (PD) properties. These properties include high intracellular accumulation in phagocytes and at sites of infection, including the prostate; broad antibiotic but also biofilm-inhibiting properties; immunomodulating and inflammation-resolving activities. These features offer particular advantages for the treatment of chronic infections of the prostate gland, which are not easily amenable to drug therapy. Macrolides may be exploited to counteract the unsatisfactory rates of clinical symptom improvement and pathogen eradication. The results of a number of clinical trials support this proposal.
Zitierstile
Harvard-Zitierstil: Perletti, G., Skerk, V., Magri, V., Markotic, A., Mazzoli, S., Parnham, M., et al. (2011) Macrolides for the treatment of chronic bacterial prostatitis: An effective application of their unique pharmacokinetic and pharmacodynamic profile (Review), Molecular Medicine Reports, 4(6), pp. 1035-1044. https://doi.org/10.3892/mmr.2011.575
APA-Zitierstil: Perletti, G., Skerk, V., Magri, V., Markotic, A., Mazzoli, S., Parnham, M., Wagenlehner, F., & Naber, K. (2011). Macrolides for the treatment of chronic bacterial prostatitis: An effective application of their unique pharmacokinetic and pharmacodynamic profile (Review). Molecular Medicine Reports. 4(6), 1035-1044. https://doi.org/10.3892/mmr.2011.575
Schlagwörter
ANTIBIOTIC SUSCEPTIBILITY; azithromycin; AZITHROMYCIN; CANCER RISK; Chlamydia trachomatis; CHLAMYDIA-TRACHOMATIS INFECTION; COMBINATION THERAPY; HEALTHY-VOLUNTEERS; macrolides; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PELVIC PAIN SYNDROME; prostatitis; SEXUALLY-TRANSMITTED INFECTIONS; Urological infections
